State Street SPDR S&P Pharmaceuticals ETF
XPH
65 hedge funds and large institutions have $256M invested in State Street SPDR S&P Pharmaceuticals ETF in 2013 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 21 increasing their positions, 18 reducing their positions, and 4 closing their positions.
275% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 4
274% more capital inflows, than outflows
Capital inflows: $88M | Capital outflows: $23.5M
18% more funds holding
Funds holding: 55 → 65 (+10)
17% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 18
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$53.3M |
| 2 |
HF
Hoxton Financial
Shepherdstown,
West Virginia
|
+$8.62M |
| 3 |
Citigroup
New York
|
+$4.14M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.5M |
| 5 |
Tower Research Capital (TRC)
New York
|
+$3.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Brinker Capital Investments
Berwyn,
Pennsylvania
|
-$5.5M |
| 2 |
Pacific Financial Group
Bellevue,
Washington
|
-$4.54M |
| 3 |
EnTrustPermal Management
New York
|
-$3.74M |
| 4 |
UBS
Zurich,
Switzerland
|
-$2.95M |
| 5 |
LPL Financial
San Diego,
California
|
-$2.02M |
XPH Hedge Fund Activity: Q4 2013 in Review
65 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q4 2013, worth a combined $256M — up 54% from $166M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new XPH positions and 4 closed out — a net gain of 11 holders — while 21 added to existing stakes and 18 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $53.3M. The largest seller was Brinker Capital Investments, exiting entirely with an estimated $5.5M sold.
- 65 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q4 2013, up from 55 in Q3 2013.
- Funds reported $256M of State Street SPDR S&P Pharmaceuticals ETF stock for Q4 2013, up 54% quarter-over-quarter.
- 15 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q4 2013 and 4 closed out, a net change of +11 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q4 2013 was Fidelity Investments, an estimated $53.3M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q4 2013 was Brinker Capital Investments, an estimated $5.5M sold.
Based on aggregated 13F filings for Q4 2013.